ProCE Banner Activity

Joining Forces: How New Approaches and Combinations Are Likely to Improve Treatment of RCC

Clinical Thought
Even prior to approval, new data from cabozantinib and combination PD-L1 and CTLA-4 inhibition are transforming treatment of metastatic RCC.

Released: November 09, 2017

Expiration: November 08, 2018

No longer available for credit.

Share

Faculty

Bradley A. McGregor

Bradley A. McGregor, MD

Instructor of Medicine
Department of Medicine
Harvard Medical School
Clinical Director
Lank Cancer for Genitourinary Oncology
Dana-Farber Cancer Institute
Boston, Massachusetts

Provided by

Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by an educational grant from

Ipsen Biopharmaceuticals Inc

Faculty Disclosure

Primary Author

Bradley A. McGregor, MD

Instructor of Medicine
Department of Medicine
Harvard Medical School
Clinical Director
Lank Cancer for Genitourinary Oncology
Dana-Farber Cancer Institute
Boston, Massachusetts

Bradley A. McGregor, MD, has disclosed that he has received consulting fees from Astellas, Exelixis, Genentech, and Seattle Genetics.